Medications for Ovarian Hyperstimulation Syndrome

5 results
Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.
Usage: ALBUMIN (HUMAN) 20% is indicated for treating hypovolemia, hypoalbuminemia in critically ill patients, preventing central volume depletion after paracentesis, managing severe ovarian hyperstimulation syndrome, aiding fluid management in adult respiratory distress syndrome, treating edema in acute nephrosis, and addressing hyperbilirubinemia in hemolytic disease of the newborn.
Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.
Usage: ALBUMIN (HUMAN) 25% is indicated for treating hypovolemia, hypoalbuminemia in critically ill or active bleeding patients, maintaining cardiovascular function post-paracentesis for cirrhotic ascites, managing severe ovarian hyperstimulation syndrome, adjunct treatment for ARDS and acute nephrosis, and treating hyperbilirubinemia in hemolytic disease of the newborn.
GRIFOLS USA, LLC
Usage: ALBUTEIN 20% is indicated for restoring blood volume in hypovolemia, treating hypoalbuminemia, aiding in cardiopulmonary bypass, managing acute nephrosis, addressing ovarian hyperstimulation syndrome, treating neonatal hyperbilirubinemia, and assisting in Adult Respiratory Distress Syndrome (ARDS) management. It helps prevent central volume depletion post-paracentesis.
GRIFOLS USA, LLC
Usage: ALBUTEIN 25% is indicated for restoring circulating blood volume in hypovolemia, treating acute nephrosis, hypoalbuminemia, and severe ovarian hyperstimulation syndrome. It serves as a plasma volume expander in conditions like neonatal hyperbilirubinemia and adult respiratory distress syndrome, and aids post-paracentesis fluid management.
GRIFOLS USA, LLC
Usage: Human Albumin Grifols 20% is indicated for restoring blood volume in hypovolemia, treating acute nephrosis and hypoalbuminemia, assisting in cardiopulmonary bypass, managing ovarian hyperstimulation syndrome, neonatal hyperbilirubinemia, and fluid overload in ARDS, as well as preventing volume depletion after paracentesis.